# IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia

Source: https://onco.cc/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/  
OnCo record `paper-royer-plasma-cell-leukaemia-ifm-jco-2016` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The first prospective trial dedicated to plasma cell leukaemia showed that a bortezomib-based four-drug induction followed by stem cell transplantation could produce remissions in most patients, though relapse remained the rule.

## Summary

Phase 2 study of 40 patients with primary plasma cell leukaemia treated with bortezomib, doxorubicin, cyclophosphamide and dexamethasone induction followed by autologous transplant and, for those with a donor, reduced-intensity allogeneic transplant, or a second autologous transplant and maintenance.

Response after induction was 69 percent, median progression-free survival 15.1 months and median overall survival 36.3 months, a clear improvement on historical series with median survival under a year.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2016
- DOI: 10.1200/JCO.2015.63.1929
- Authors: Royer B, Minvielle S, Diouf M, et al.
- Findings: Overall response 69 percent after induction.; Median progression-free survival 15.1 months; median overall survival 36.3 months.
- What it means: Bortezomib-based induction with early transplant consolidation became the accepted approach for fit patients with this rare aggressive disease; daratumumab-containing quadruplets are now added by extrapolation.
- Caveats: Small single-arm study.; Allogeneic transplant did not clearly improve outcomes compared with tandem autologous transplant.

## Sources

- J Clin Oncol 2016: https://doi.org/10.1200/JCO.2015.63.1929
- PubMed: https://pubmed.ncbi.nlm.nih.gov/27114594/

## Connected records

- cancers: [Plasma cell leukaemia](https://onco.cc/cancers/plasma-cell-leukaemia/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-royer-plasma-cell-leukaemia-ifm-jco-2016.json